"Bipolar Disorder - US Drug Forecast and Market Analysis to 2024" Published

From: Fast Market Research, Inc.
Published: Wed Jun 22 2016

Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka's Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.

Full Report Details at
- http://www.fastmr.com/prod/1185922_bipolar_disorder_us_drug.aspx?afid=301

GlobalData estimates that drug sales for bipolar disorder in the US reached $4.5 billion during 2014, making the US the largest market within the 8MM. A steep decline in sales is forecast to occur between 2015 and 2017, attributed largely to the generic erosion of Otsuka's Abilify. This will be followed by a more gradual contraction in market size between 2017 and 2020 due to the generic erosion of other key brands such as Dainippon Sumitomo's Latuda and AstraZeneca's Seroquel XR.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Report Scope

* Overview of Bipolar Disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in the US from 2014-2024.
* Analysis of the impact of key events as well the drivers and restraints affecting the US Bipolar Disorder market.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Bipolar Disorder.
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2014-2024 in US.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
- Bipolar Disorder - 5EU Drug Forecast and Market Analysis to 2024
- Bipolar Disorder - Canada Drug Forecast and Market Analysis to 2024
- Bipolar Disorder - Japan Drug Forecast and Market Analysis to 2024
- EpiCast Report: Bipolar Disorder - Epidemiology Forecast to 2024

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »